tradingkey.logo

Maravai LifeSciences Holdings Inc

MRVI
3.270USD
-0.030-0.91%
收盤 12/26, 16:00美東報價延遲15分鐘
473.23M總市值
虧損本益比TTM

Maravai LifeSciences Holdings Inc

3.270
-0.030-0.91%

關於 Maravai LifeSciences Holdings Inc 公司

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Maravai LifeSciences Holdings Inc簡介

公司代碼MRVI
公司名稱Maravai LifeSciences Holdings Inc
上市日期Nov 20, 2020
CEOBrust (Bernd)
員工數量570
證券類型Ordinary Share
年結日Nov 20
公司地址10770 Wateridge Circle Suite 200
城市SAN DIEGO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92121
電話18585460004
網址https://www.maravai.com/
公司代碼MRVI
上市日期Nov 20, 2020
CEOBrust (Bernd)

Maravai LifeSciences Holdings Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
339.36K
+1.28%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
175.77K
+131.98%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
+110.36%
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
+182.23%
Dr. John A. Deford, Ph.D.
Dr. John A. Deford, Ph.D.
Independent Director
Independent Director
--
--
Mr. Sean L. Cunningham
Mr. Sean L. Cunningham
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
339.36K
+1.28%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
175.77K
+131.98%

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
North America
30.64M
64.64%
Europe, the Middle East and Africa
8.39M
17.71%
Asia Pacific
8.16M
17.21%
Latin and Central America
327.00K
0.69%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
GTCR Golder Rauner, LLC
13.89%
12 West Capital Management, L.P.
8.63%
Hudson View Capital LLC
6.17%
Braidwell LP
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
其他
60.24%
持股股東
持股股東
佔比
GTCR Golder Rauner, LLC
13.89%
12 West Capital Management, L.P.
8.63%
Hudson View Capital LLC
6.17%
Braidwell LP
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
其他
60.24%
股東類型
持股股東
佔比
Investment Advisor
29.58%
Hedge Fund
25.00%
Investment Advisor/Hedge Fund
17.45%
Private Equity
13.89%
Individual Investor
6.63%
Corporation
6.17%
Research Firm
4.39%
Pension Fund
0.20%
Bank and Trust
0.14%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
518
128.65M
88.93%
-44.43M
2025Q2
560
144.27M
100.21%
-25.80M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
2023Q3
641
137.53M
104.23%
-17.92M
2023Q2
646
129.68M
98.32%
-22.48M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
GTCR Golder Rauner, LLC
20.15M
13.93%
--
--
Jun 30, 2025
12 West Capital Management, L.P.
12.52M
8.65%
--
--
Jun 30, 2025
Hudson View Capital LLC
6.87M
4.75%
+6.87M
--
May 21, 2025
Braidwell LP
8.35M
5.77%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.41M
5.81%
+52.73K
+0.63%
Jun 30, 2025
The Vanguard Group, Inc.
9.38M
6.48%
-2.26M
-19.38%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
2.64M
1.83%
+2.64M
--
Jun 30, 2025
Mackenzie Investments
6.07M
4.2%
-44.32K
-0.72%
Jun 30, 2025
Renaissance Technologies LLC
4.19M
2.89%
+75.50K
+1.84%
Jun 30, 2025
Mirabella Financial Services LLP
3.75M
2.59%
+10.05K
+0.27%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Global X Genomics & Biotechnology ETF
0.41%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Global X Genomics & Biotechnology ETF
佔比0.41%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
iShares Biotechnology ETF
佔比0.03%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.02%
Schwab U.S. Small-Cap ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Maravai LifeSciences Holdings Inc的前五大股東是誰?

Maravai LifeSciences Holdings Inc的前五大股東如下:
GTCR Golder Rauner, LLC
持有股份:20.15M
佔總股份比例:13.93%。
12 West Capital Management, L.P.
持有股份:12.52M
佔總股份比例:8.65%。
Hudson View Capital LLC
持有股份:6.87M
佔總股份比例:4.75%。
Braidwell LP
持有股份:8.35M
佔總股份比例:5.77%。
BlackRock Institutional Trust Company, N.A.
持有股份:8.41M
佔總股份比例:5.81%。

Maravai LifeSciences Holdings Inc的前三大股東類型是什麼?

Maravai LifeSciences Holdings Inc 的前三大股東類型分別是:
GTCR Golder Rauner, LLC
12 West Capital Management, L.P.
Hudson View Capital LLC

有多少機構持有Maravai LifeSciences Holdings Inc(MRVI)的股份?

截至2025Q3,共有518家機構持有Maravai LifeSciences Holdings Inc的股份,合計持有的股份價值約為128.65M,占公司總股份的88.93% 。與2025Q2相比,機構持股有所增加,增幅為-11.28%。

哪個業務部門對Maravai LifeSciences Holdings Inc的收入貢獻最大?

在FY2025Q2,--業務部門對Maravai LifeSciences Holdings Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI